162 related articles for article (PubMed ID: 12586733)
1. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.
Pompl PN; Ho L; Bianchi M; McManus T; Qin W; Pasinetti GM
FASEB J; 2003 Apr; 17(6):725-7. PubMed ID: 12586733
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.
Drachman DB; Frank K; Dykes-Hoberg M; Teismann P; Almer G; Przedborski S; Rothstein JD
Ann Neurol; 2002 Dec; 52(6):771-8. PubMed ID: 12447931
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis.
Almer G; Guégan C; Teismann P; Naini A; Rosoklija G; Hays AP; Chen C; Przedborski S
Ann Neurol; 2001 Feb; 49(2):176-85. PubMed ID: 11220737
[TBL] [Abstract][Full Text] [Related]
4. Is prostaglandin E(2) a pathogenic factor in amyotrophic lateral sclerosis?
Almer G; Kikuchi H; Teismann P; Przedborski S
Ann Neurol; 2006 Jun; 59(6):980-3. PubMed ID: 16619237
[TBL] [Abstract][Full Text] [Related]
5. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.
Klivenyi P; Kiaei M; Gardian G; Calingasan NY; Beal MF
J Neurochem; 2004 Feb; 88(3):576-82. PubMed ID: 14720207
[TBL] [Abstract][Full Text] [Related]
6. Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS.
Azari MF; Profyris C; Le Grande MR; Lopes EC; Hirst J; Petratos S; Cheema SS
Eur J Neurol; 2005 May; 12(5):357-64. PubMed ID: 15804265
[TBL] [Abstract][Full Text] [Related]
7. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis.
Kiaei M; Kipiani K; Petri S; Choi DK; Chen J; Calingasan NY; Beal MF
J Neurochem; 2005 Apr; 93(2):403-11. PubMed ID: 15816863
[TBL] [Abstract][Full Text] [Related]
8. Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model.
Fellner A; Barhum Y; Angel A; Perets N; Steiner I; Offen D; Lev N
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28763002
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis.
Drachman DB; Rothstein JD
Ann Neurol; 2000 Nov; 48(5):792-5. PubMed ID: 11079544
[TBL] [Abstract][Full Text] [Related]
10. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis.
Yoo YE; Ko CP
Exp Neurol; 2011 Sep; 231(1):147-59. PubMed ID: 21712032
[TBL] [Abstract][Full Text] [Related]
11. Induction of cyclooxygenase-2 in reactive glial cells by the CD40 pathway: relevance to amyotrophic lateral sclerosis.
Okuno T; Nakatsuji Y; Kumanogoh A; Koguchi K; Moriya M; Fujimura H; Kikutani H; Sakoda S
J Neurochem; 2004 Oct; 91(2):404-12. PubMed ID: 15447673
[TBL] [Abstract][Full Text] [Related]
12. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis.
Liang X; Wang Q; Shi J; Lokteva L; Breyer RM; Montine TJ; Andreasson K
Ann Neurol; 2008 Sep; 64(3):304-14. PubMed ID: 18825663
[TBL] [Abstract][Full Text] [Related]
13. Regulation of system x(c)- in the SOD1-G93A mouse model of ALS.
Albano R; Liu X; Lobner D
Exp Neurol; 2013 Dec; 250():69-73. PubMed ID: 24041987
[TBL] [Abstract][Full Text] [Related]
14. A role for the urokinase-type plasminogen activator system in amyotrophic lateral sclerosis.
Glas M; Popp B; Angele B; Koedel U; Chahli C; Schmalix WA; Anneser JM; Pfister HW; Lorenzl S
Exp Neurol; 2007 Oct; 207(2):350-6. PubMed ID: 17716658
[TBL] [Abstract][Full Text] [Related]
15. Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model.
Park JH; Hong YH; Kim HJ; Kim SM; Kim MJ; Park KS; Sung JJ; Lee KW
Neurosci Lett; 2007 Feb; 413(3):265-9. PubMed ID: 17174029
[TBL] [Abstract][Full Text] [Related]
16. Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis.
Maihöfner C; Probst-Cousin S; Bergmann M; Neuhuber W; Neundörfer B; Heuss D
Eur J Neurosci; 2003 Sep; 18(6):1527-34. PubMed ID: 14511332
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin modulates the immune-inflammatory response of a SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).
Noh MY; Cho KA; Kim H; Kim SM; Kim SH
Neurosci Lett; 2014 Jun; 574():53-8. PubMed ID: 24820540
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation.
Koh SH; Kim Y; Kim HY; Cho GW; Kim KS; Kim SH
Eur J Neurosci; 2007 Apr; 25(7):1923-30. PubMed ID: 17439481
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS.
Koh SH; Kim Y; Kim HY; Hwang S; Lee CH; Kim SH
Exp Neurol; 2007 Jun; 205(2):336-46. PubMed ID: 17433298
[TBL] [Abstract][Full Text] [Related]
20. SK-PC-B70M alleviates neurologic symptoms in G93A-SOD1 amyotrophic lateral sclerosis mice.
Seo JS; Baek IS; Leem YH; Kim TK; Cho Y; Lee SM; Park YH; Han PL
Brain Res; 2011 Jan; 1368():299-307. PubMed ID: 20971081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
